Clinical trials: Adjuvant Drug Therapy
Carcinoma, Non-Small-Cell Lung
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected…
- Trial name
- MERMAID-1 (NCT04385368)
- Testing
- Durvalumab + SoC chemotherapy
- Where
- 140 sites in United States, Argentina and 31 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Breast Cancer Female
Personalized Vaccine for TNBC Immunotherapy
Due to their genetic instability, breast tumors that do not express receptors for Estrogens, Progestagens or amplify the Her2 / neu oncogene [called triple-negative breast cancer (TNBC)] and other tumors such as melanoma…
- Trial name
- TEBICA003 TNBC (NCT06195618)
- Testing
- Peptide (neoantigen) pulsed autologous Dendritic cell
- Where
- Colombia
- Volunteers
- 8 people
- Sponsor
- Universidad Nacional de Colombia
Breast Cancer
Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy
Neoadjuvant chemotherapy is standard therapy for the management of localised breast cancer, and makes it possible to evaluate tumour response.
- Trial name
- PRIMUNEO (NCT01513408)
- Testing
- immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Centre Georges Francois Leclerc
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy.
- Conditions
- Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
- Trial name
- NCT01595074
- Testing
- medical chart review, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 950 people
- Sponsor
- National Cancer Institute (NCI)
Stage II Colon Cancer, Stage III Colon Cancer
Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer
According to general medical guidelines, adjuvant chemotherapy is used after curative resection of high-risk stage II or III primary colon cancer.
- Trial name
- OCEAN (NCT04416490)
- Where
- South Korea
- Volunteers
- 2,013 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Triple Negative Breast Cancer
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
This is a single arm, pilot study assessing safety/feasibility and efficacy of neo-adjuvant glembatumumab vedotin (GV) in patients with high risk triple negative breast cancer (TNBC) with glycoprotein-NMB (gpNMB) expression ≥…
- Trial name
- Breast50 (NCT03473691)
- Testing
- Glembatumumab Vedotin
- Sponsor
- University of Virginia
Pancreatic Cancer
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.
- Trial name
- NCT05911217
- Testing
- CT041 autologous CAR T-cell injection
- Where
- 8 sites in China
- Volunteers
- 20 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Uterine Leiomyosarcoma
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
To find out if receiving standard chemotherapy (doxorubicin and trabectedin) can extend the cancer-free survival of patients with Stage 1b/2 uterine leiomyosarcoma who had surgery that fully removed the tumor.
- Trial name
- NCT07076186
- Testing
- Trabectedin, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay
The primary objective of this study is to assess the extent to which the Prosigna™ Breast Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and…
- Trial name
- NCT01899079
- Where
- 7 sites in Spain
- Volunteers
- 217 people
- Sponsor
- NanoString Technologies, Inc.
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05726370
- Testing
- Pembrolizumab, CISPLATIN, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Dana-Farber Cancer Institute
Resectable Pancreatic Duct Adenocarcinoma
Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma
In patients with resectable pancreatic duct adenocarcinoma (PDAC), curative surgery followed by adjuvant chemotherapy is currently the standard of care.
- Trial name
- PANACHE01 (NCT02959879)
- Testing
- FOLFOX neoadjuvant chemotherapy, FOLFIRINOX neoadjuvant chemotherapy, curative surgery for resectable pancreatic duct adenocarcinoma
- Where
- France
- Volunteers
- 153 people
- Sponsor
- University Hospital, Rouen
Glioblastoma, Gliosarcoma
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly…
- Trial name
- Intellance1 (NCT02573324)
- Testing
- Temozolomide, Depatuxizumab mafodotin, Radiation
- Where
- 212 sites in United States, Argentina and 26 more
- Volunteers
- 691 people
- Sponsor
- AbbVie
Ovarian Cancer
Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy
This is a first-in-human, open label phase I study in ovarian cancer patients with primary disease eligible for standard-of-care treatment with neo-adjuvant chemotherapy, i.e.
- Trial name
- OLIVIA (NCT04163094)
- Testing
- W_ova1 Vaccine
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- University Medical Center Groningen
Breast Cancer Female
Women With Breast Cancer Undergoing Chemotherapy: Implications in Quality of Life
Breast cancer is a major public health problem and is the main cancer disease in women worldwide and in Europe. In Portugal it is the most common cancer, the third cause of cancer death, following the European trend.
- Trial name
- NCT03585218
- Testing
- Inhalation of essential oils
- Where
- Portugal
- Volunteers
- 112 people
- Sponsor
- University of Minho
Breast Cancer
CHEmotherapy and Cognitive Deterioration in Patients With Operable Breast Cancer: Impact of Cognitive Rehabilitation (CHEMOFOG)
An interventional, non-pharmacological, monocentric study evaluating the effectiveness of cognitive rehabilitation in counteracting chemotherapy-induced cognitive impairment (CRCI) in women with operable breast cancer treated…
- Trial name
- CHEMOFOG (NCT06435559)
- Testing
- Neurotablet® and Neuropsychological evaluations, Neuropsychological evaluations
- Volunteers
- 128 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Retinoblastoma
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.
- Trial name
- NCT05080010
- Testing
- 3 cycles chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
This study is a prospective, single-arm, phase II clinical study. Screening patients with stage III GC/GEJ adenocarcinoma after D2 or broader radical resection.
- Trial name
- NCT06761846
- Testing
- Sintilimab plus Chemotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Epilepsy, Drug Resistant
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)
The aim of this study is to evaluate the clinical efficacy of sirolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive…
- Trial name
- NCT06719791
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Xuanwu Hospital, Beijing
Breast Cancer
Cognition in Breast Cancer Patients: The Impact of Cancer-related Stress
The study will investigate the impact of cancer-related stress and its consequences (acute and posttraumatic stress symptoms, altered cortisol secretion) on cognitive function in breast cancer patients.
- Trial name
- Cognicares (NCT01264562)
- Where
- 6 sites in Germany
- Volunteers
- 254 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Lung Cancer
Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01059188
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 15 sites in Switzerland
- Volunteers
- 69 people
- Sponsor
- Swiss Cancer Institute